Literature DB >> 17591846

Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.

David M Whiley1, E Athena Limnios, Sanghamitra Ray, Theo P Sloots, John W Tapsall.   

Abstract

Increasing numbers of Neisseria gonorrhoeae strains with decreased susceptibilities to ceftriaxone and other oral cephalosporins widely used for the treatment of gonorrhea have been isolated in Sydney, Australia, over several years. In this study, we examined the complete penicillin-binding protein 2 (PBP 2) amino acid sequences of 109 gonococci, selected on the basis of their diverse temporal and geographic origins and because they exhibited a range of ceftriaxone MICs: < OR =0.03 microg/ml (n = 59), 0.06 microg/ml (n = 43), and 0.125 microg/ml (n = 7). Auxotyping, serotyping, and genotyping by N. gonorrhoeae multiantigen sequence typing sequence-based analysis was also performed. In total, 20 different amino acid sequence patterns were identified, indicating considerable variation in the PBP 2 sequences in this study sample. Only some of the N. gonorrhoeae isolates with significantly higher ceftriaxone MICs contained a mosaic PBP 2 pattern, while more isolates exhibited a nonmosaic PBP 2 pattern containing an A501V substitution. Although particular N. gonorrhoeae genotypes in our sample were shown to be less susceptible to ceftriaxone, the reduced susceptibility to ceftriaxone was not specific to any particular genotype and was observed in a broad range of auxotypes, serotypes, and genotypes. Overall, the results of our study show that N. gonorrhoeae strains exhibiting reduced sensitivity to ceftriaxone are not of a particular subtype and that a number of different mutations in PBP 2 may contribute to this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591846      PMCID: PMC2043202          DOI: 10.1128/AAC.00306-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  The antibiotic susceptibility of Neisseria gonorrhoeae isolated in Ulaanbaatar, Mongolia.

Authors:  E Lkhamsuren; T R Shultz; E A Limnios; J W Tapsall
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

2.  Epidemiological characteristics and molecular basis of fluoroquinolone-resistant Neisseria gonorrhoeae strains isolated in Korea and nearby countries.

Authors:  Dongeun Yong; Tae Sook Kim; Jong Rak Choi; Jong Hwa Yum; Kyungwon Lee; Yunsop Chong; Hee-Bok Oh; Tiffany Shultz; John W Tapsall
Journal:  J Antimicrob Chemother       Date:  2004-07-01       Impact factor: 5.790

3.  Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area.

Authors:  Iona M C Martin; Catherine A Ison; David M Aanensen; Kevin A Fenton; Brian G Spratt
Journal:  J Infect Dis       Date:  2004-03-31       Impact factor: 5.226

4.  Hybrid penicillin-binding proteins in penicillin-resistant strains of Neisseria gonorrhoeae.

Authors:  B G Spratt
Journal:  Nature       Date:  1988-03-10       Impact factor: 49.962

5.  Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae.

Authors:  Patricia A Ropp; Mei Hu; Melanie Olesky; Robert A Nicholas
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  Serological classification of Neisseria gonorrhoeae with use of monoclonal antibodies to gonococcal outer membrane protein I.

Authors:  J S Knapp; M R Tam; R C Nowinski; K K Holmes; E G Sandström
Journal:  J Infect Dis       Date:  1984-07       Impact factor: 5.226

Review 7.  Applications of molecular testing in clinical laboratories for the diagnosis and control of gonorrhea.

Authors:  John Tapsall; David Whiley; Theo Sloots
Journal:  Future Microbiol       Date:  2006-10       Impact factor: 3.165

8.  Penicillin-binding proteins of penicillin-susceptible and intrinsically resistant Neisseria gonorrhoeae.

Authors:  T J Dougherty; A E Koller; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

9.  Development of a defined minimal medium for the growth of Neisseria gonorrhoeae.

Authors:  L J La Scolea; F E Young
Journal:  Appl Microbiol       Date:  1974-07

10.  Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime.

Authors:  Satoshi Ameyama; Shoichi Onodera; Masahiro Takahata; Shinzaburo Minami; Nobuko Maki; Katsuhisa Endo; Hirokazu Goto; Hiroo Suzuki; Yukihiko Oishi
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

View more
  50 in total

1.  Characteristics and dissemination of mosaic penicillin-binding protein 2-harboring multidrug-resistant Neisseria gonorrhoeae isolates with reduced cephalosporin susceptibility in northern Taiwan.

Authors:  Chung-Ter Huang; Muh-Yong Yen; Wing-Wai Wong; Lan-Hui Li; Kun-Yen Lin; Mei-Hui Liao; Shu-Ying Li
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

2.  Molecular Assay for Detection of Genetic Markers Associated with Decreased Susceptibility to Cephalosporins in Neisseria gonorrhoeae.

Authors:  S W Peterson; I Martin; W Demczuk; A Bharat; L Hoang; J Wylie; V Allen; B Lefebvre; G Tyrrell; G Horsman; D Haldane; R Garceau; T Wong; M R Mulvey
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

3.  Alanine 501 Mutations in Penicillin-Binding Protein 2 from Neisseria gonorrhoeae: Structure, Mechanism, and Effects on Cephalosporin Resistance and Biological Fitness.

Authors:  Joshua Tomberg; Alena Fedarovich; Leah R Vincent; Ann E Jerse; Magnus Unemo; Christopher Davies; Robert A Nicholas
Journal:  Biochemistry       Date:  2017-02-16       Impact factor: 3.162

4.  Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada.

Authors:  Vanessa G Allen; David J Farrell; Anuradha Rebbapragada; Jingyuan Tan; Nathalie Tijet; Stephen J Perusini; Lynn Towns; Stephen Lo; Donald E Low; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

5.  Recognition of the β-lactam carboxylate triggers acylation of Neisseria gonorrhoeae penicillin-binding protein 2.

Authors:  Avinash Singh; Joshua Tomberg; Robert A Nicholas; Christopher Davies
Journal:  J Biol Chem       Date:  2019-07-30       Impact factor: 5.157

6.  Equations To Predict Antimicrobial MICs in Neisseria gonorrhoeae Using Molecular Antimicrobial Resistance Determinants.

Authors:  Walter Demczuk; Irene Martin; Pam Sawatzky; Vanessa Allen; Brigitte Lefebvre; Linda Hoang; Prenilla Naidu; Jessica Minion; Paul VanCaeseele; David Haldane; David W Eyre; Michael R Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

7.  A Case of Decreased Susceptibility to Ceftriaxone in Neisseria gonorrhoeae in the Absence of a Mosaic Penicillin-Binding Protein 2 (penA) Allele.

Authors:  A Jeanine Abrams; Robert D Kirkcaldy; Kevin Pettus; Jan L Fox; Grace Kubin; David L Trees
Journal:  Sex Transm Dis       Date:  2017-08       Impact factor: 2.830

Review 8.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

9.  Crystal structures of penicillin-binding protein 2 from penicillin-susceptible and -resistant strains of Neisseria gonorrhoeae reveal an unexpectedly subtle mechanism for antibiotic resistance.

Authors:  Ailsa J Powell; Joshua Tomberg; Ashley M Deacon; Robert A Nicholas; Christopher Davies
Journal:  J Biol Chem       Date:  2008-11-04       Impact factor: 5.157

Review 10.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.